ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions

ClinicalTrials.gov ID: NCT03208985

Public ClinicalTrials.gov record NCT03208985. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Open-Label Trial Investigating Behavior Related to Ella® Use in a Simulated OTC Environment (LIBRella)

Study identification

NCT ID
NCT03208985
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
HRA Pharma
Industry
Enrollment
1,270 participants

Conditions and interventions

Interventions

  • Use Phase (Ulipristal Acetate, 30 mg) Drug

Drug

Eligibility (public fields only)

Age range
Not listed
Sex
Female
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 22, 2017
Primary completion
Jun 13, 2018
Completion
Jun 13, 2018
Last update posted
Dec 1, 2022

2017 – 2018

United States locations

U.S. sites
34
U.S. states
13
U.S. cities
30
Facility City State ZIP Site status
HRA Pharma Investigational Site Rancho Cucamonga California 91730
HRA Pharma Investigational Site Boulder Colorado 80302
HRA Pharma Investigational Site Denver Colorado 80003
HRA Pharma Investigational Site Denver Colorado 80207
HRA Pharma Investigational Site Fort Myers Florida 33919
HRA Pharma Investigational Site Miami Florida 33133
HRA Pharma Investigational Site Orlando Florida 32817
HRA Pharma Investigational Site Pembroke Pines Florida 33026
HRA Pharma Investigational Site St. Petersburg Florida 33701
HRA Pharma Investigational Site Tampa Florida 33617
HRA Pharma Investigational Site Belleville Illinois 62226
HRA Pharma Investigational Site Andover Minnesota 55304
HRA Pharma Investigational Site Saint Louis Park Minnesota 55426
HRA Pharma Investigational Site City of Saint Peters Missouri 63376
HRA Pharma Investigational Site Kansas City Missouri 64111
HRA Pharma Investigational Site Manchester Missouri 63088
HRA Pharma Investigational Site St Louis Missouri 63108
HRA Pharma Investigational Site St Louis Missouri 63118
HRA Pharma Investigational Site Las Vegas Nevada 89102
HRA Pharma Investigational Site Hackensack New Jersey 07601
HRA Pharma Investigational Site Morristown New Jersey 07960
HRA Pharma Investigational Site New Brunswick New Jersey 08901
HRA Pharma Investigational Site Trenton New Jersey 08608
HRA Pharma Investigational Site Albuquerque New Mexico 87104
HRA Pharma Investigational Site Albuquerque New Mexico 87109
HRA Pharma Investigational Site New York New York 10012
HRA Pharma Investigational Site Durham North Carolina 27704
HRA Pharma Investigational Site Raleigh North Carolina 27603
HRA Pharma Investigational Site Portland Oregon 97212
HRA Pharma Investigational Site Bremerton Washington 98310
HRA Pharma Investigational Site Puyallup Washington 98373
HRA Pharma Investigational Site Seattle Washington 98122
HRA Pharma Investigational Site Seattle Washington 98133
HRA Pharma Investigational Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03208985, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 1, 2022 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03208985 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →